| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/25/2005 | EP1531808A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions |
| 05/25/2005 | EP1531807A1 Bazedoxifene treatment regimens |
| 05/25/2005 | EP1531805A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 05/25/2005 | EP1531799A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
| 05/25/2005 | EP1531793A1 Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent |
| 05/25/2005 | EP1531791A2 Prevention and reduction of blood loss |
| 05/25/2005 | EP1531716A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs |
| 05/25/2005 | EP1287137B1 REGULATION OF HUMAN $g(a)1A?ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
| 05/25/2005 | EP1286673B1 Ligands of integrin receptors |
| 05/25/2005 | EP1282592B1 Use of amines |
| 05/25/2005 | EP1163335B1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION |
| 05/25/2005 | EP1054993B1 PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
| 05/25/2005 | EP0994903B1 Methods and compositions for galactosylated glycoproteins |
| 05/25/2005 | EP0967221B1 Process for preparing pharmacologically acceptable salts of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanyl amino acids |
| 05/25/2005 | EP0966304B1 Site-specific drug delivery |
| 05/25/2005 | EP0813416B1 Reduction of infarct volume using citicoline |
| 05/25/2005 | CN1620510A Cytokine protein family |
| 05/25/2005 | CN1620467A Secreted protein |
| 05/25/2005 | CN1620466A Cystine-knot fold protein |
| 05/25/2005 | CN1620461A 2-amino-propanol derivatives |
| 05/25/2005 | CN1620458A 噻吩并嘧啶 Thienopyrimidine |
| 05/25/2005 | CN1620457A Tetracyclic heterocompounds as estrogen receptor modulators |
| 05/25/2005 | CN1620452A 3, 4-dihydro-1h-isoquinoloin-2-yl-derivatives |
| 05/25/2005 | CN1620440A Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| 05/25/2005 | CN1620438A 5, 6-diaryl-pyrazine-2-amide derivatives as CBI antagonists |
| 05/25/2005 | CN1620435A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 05/25/2005 | CN1620434A Pyrrolidine-2-ones as factor Xa inhibitors |
| 05/25/2005 | CN1620433A Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 05/25/2005 | CN1620430A 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR-alpha |
| 05/25/2005 | CN1620429A Derivatives of alpha-phenylthiocarboxylic and g(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPAR alpha activation |
| 05/25/2005 | CN1620424A Compounds for the treatment of inflammatory disorders |
| 05/25/2005 | CN1620423A Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR) |
| 05/25/2005 | CN1620422A Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR) |
| 05/25/2005 | CN1620325A Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| 05/25/2005 | CN1620314A Gas micro-liposome compound |
| 05/25/2005 | CN1620313A Method of examining effect of angiogenesis inhibitors mediated by the inhibition of integrin expression |
| 05/25/2005 | CN1620308A Use of a pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
| 05/25/2005 | CN1620301A Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 05/25/2005 | CN1620300A Method of administering bisphosphonates |
| 05/25/2005 | CN1620294A Pyrimidine A2b selective antagonist compounds, their synthesis and use |
| 05/25/2005 | CN1620293A Polymorphs of clopidogrel hydrogensulfate |
| 05/25/2005 | CN1620291A 3-(imidazolyl)-2-alkoxypropanoic acids as TAFIA inhibitors |
| 05/25/2005 | CN1620283A Dispersions for formulating slightly or poorly soluble active ingredients |
| 05/25/2005 | CN1619312A Specific markers for metabolic syndrome |
| 05/25/2005 | CN1618803A Recombinated phycobiliprotein and its preparation method and application |
| 05/25/2005 | CN1618798A Preparation process of isosorbide mononitrate |
| 05/25/2005 | CN1618796A 4, 5-disubstituted-2-(1-substituted-1 H-pyrrole-2-radical)-thiazole derivative |
| 05/25/2005 | CN1618455A Traditional Chinese medicine pill for treating cerebral thrombosis, and its prescription |
| 05/25/2005 | CN1618445A Medicine for treating cardiovascular disease, and its prepn. method |
| 05/25/2005 | CN1618435A Oral liquor for promoting-blood circulation and removing blood stasis contg. Radix astragali and ginseng |
| 05/25/2005 | CN1618433A Medicine prepared with inosine and fructose composition |
| 05/25/2005 | CN1618429A Slow-release double-layer tablet for treating and preventing apoplexy, and its prepn. method |
| 05/25/2005 | CN1618426A Medicinal composition contg. katopril, and its prepn. method |
| 05/25/2005 | CN1618425A Composition contg. theaflavin and its derivatives, prepn. method and application thereof |
| 05/25/2005 | CN1618303A Health-care oil for preventing cardiovascular and cerebrovascular disease |
| 05/25/2005 | CN1203090C Cyclic bonding inhibitor |
| 05/25/2005 | CN1203087C Factor VIIa inhibitors |
| 05/25/2005 | CN1203070C Thrombin receptor antagonists |
| 05/25/2005 | CN1203060C Pyridine derivatives, its composition and use |
| 05/25/2005 | CN1203059C Novel processes for preparing torsemide intermediate |
| 05/25/2005 | CN1203058C Piperidine derivatives and drugs containing these derivatives as active ingredient |
| 05/25/2005 | CN1203047C Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| 05/25/2005 | CN1202854C Chinese medicine possessing kidney supplementing, brain fortifying, statis transforming and vessel freeing actions |
| 05/25/2005 | CN1202840C Microwave inducing method for extracting action components from root of kudzuvine |
| 05/25/2005 | CN1202836C Toad skin preparation and productive process thereof |
| 05/25/2005 | CN1202832C High-activity ginkgo leaf extract preparation and application |
| 05/25/2005 | CN1202828C Use of diphosphonic acid in preparing medicine for treatment of vasculogenesis |
| 05/25/2005 | CN1202825C Difenidol hydrochloride oral disintegrating tablet and prparation process thereof |
| 05/25/2005 | CN1202823C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack |
| 05/25/2005 | CN1202822C Nimodipine slow release capsule and its preparation method |
| 05/25/2005 | CN1202821C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (MIDDM) attack |
| 05/25/2005 | CN1202815C Delayed-action form of administration containing tramadol saccharinate |
| 05/24/2005 | US6897319 Therapeutic drugs for treating central nervous system disorders |
| 05/24/2005 | US6897318 Process for making substituted pyrazoles |
| 05/24/2005 | US6897317 For therapy of arteriosclerosis and dyslipidaemias |
| 05/24/2005 | US6897310 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction |
| 05/24/2005 | US6897298 Method for extracting a compound from a ginseng spp. plant, ginseng or pseudo-ginseng |
| 05/24/2005 | US6897293 A DNA sequence encoding a gax protein or portion, which inhibits vascular smooth muscle cell proliferation, useful in the treatment of blood vessel diseases |
| 05/24/2005 | US6897290 Regulators of complement activation (RCA); diagnosis/therapy of complement system for autoimmune disease treatment; open reading frames; point mutations; membrane cofactor/decay accelerating factor/factor H |
| 05/24/2005 | US6897239 New use of existing pharmaceutical misoprostol antiulcer agent, has a strong local vasodilation effect on applied tissue; a synergic action with combining alprostadil |
| 05/24/2005 | US6897232 Activate soluble guanylate cyclase; for use treating cardiovascular disorders, erectile dysfunction, diabetes, and cirrhosis of the liver, kidney disorders, and learning disability |
| 05/24/2005 | US6897231 Jun n- terminal kinase inhibitors such as 3-(4-methoxyphenyl)-1H-indazole |
| 05/24/2005 | US6897229 Use of PDE4 inhibitor N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide, salts or its N-oxide with PDE3 inhibitor for treatment of obstructions of bronchi |
| 05/24/2005 | US6897226 NK-1 receptor active amine oxide prodrugs |
| 05/24/2005 | US6897222 Pyrido[2,1-a]isoquinoline derivatives |
| 05/24/2005 | US6897219 Central nervous system diosrders; analgesics; antiinflammatory agents |
| 05/24/2005 | US6897218 Nitric oxide donors based on metallic centers |
| 05/24/2005 | US6897210 Anticancer agents; antiarthritic agents |
| 05/24/2005 | US6897209 Thrombosis; anticholesterol agents; cardiovascular disorders; antiinflammatory agents; anticancer agents |
| 05/24/2005 | US6897207 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors |
| 05/24/2005 | US6897203 Polysaccharidic esters of retinoic acid |
| 05/24/2005 | US6897198 Method of treatment with combinations of statin and aryl-substituted propanolamine derivatives |
| 05/24/2005 | US6897050 Desaturase genes and their use |
| 05/24/2005 | US6897039 For treatment of cardiovascular diseases. |
| 05/24/2005 | US6897030 CDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in |
| 05/24/2005 | US6896652 Cardiac disease treatment and device |
| 05/24/2005 | CA2326076C Novel macrolides |
| 05/24/2005 | CA2155840C Hydroxymethyl furazane carboxylic acid derivatives and their use in the treatment of cardio-vascular conditions |
| 05/24/2005 | CA2132847C Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents |
| 05/20/2005 | CA2487657A1 Specific markers for metabolic syndrome |